A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Active, not recruiting · NCT06393712 · Registry updated 2026-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy | Nutritional and Metabolic Diseases, amyloidosis, brain disorder, cardiovascular disorder, central nervous system disorder, cerebral amyloid angiopathy, cerebral arterial disease, cerebrovascular disorder, intracranial arterial disease, metabolic disease, nervous system disorder, proteostasis deficiencies, vascular disorder | Active, not recruiting | Phase 2 | 2026-09-18 | NCT06393712 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alnylam Pharmaceuticals | 27 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||